AQR Capital Management
TRDA icon

AQR Capital Management’s Entrada Therapeutics TRDA Stock Holding History

AQR Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Buy
79,493
+53,239
+203% +$610K ﹤0.01% 2769
2025
Q4 		$270K Buy
26,254
+12,263
+88% +$103K ﹤0.01% 3218
2025
Q3 		$81.1K Sell
13,991
-21,629
-61% -$127K ﹤0.01% 3388
2025
Q2 		$239K Buy
35,620
+4,701
+15% +$37.8K ﹤0.01% 2968
2025
Q1 		$280K Sell
30,919
-24,060
-44% -$300K ﹤0.01% 2722
2024
Q4 		$951K Buy
54,979
+15,511
+39% +$281K ﹤0.01% 1911
2024
Q3 		$631K Buy
+39,468
New +$622K ﹤0.01% 2066

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's TRDA Position: Q1 2026 in Review

AQR Capital Management increased its Entrada Therapeutics (TRDA) stake by 203% in Q1 2026, buying an estimated $610K and bringing the position to 79,493 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

AQR Capital Management first reported a position in TRDA in Q3 2024 and has held it in 7 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • AQR Capital Management held 79,493 shares of Entrada Therapeutics worth $1M as of Q1 2026.
  • AQR Capital Management bought 53,239 Entrada Therapeutics shares in Q1 2026, an estimated $610K.
  • Entrada Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2769 holding.
  • AQR Capital Management first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.